Docetaxel + Degarelix for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to look at patient outcomes when docetaxel is started prior to ADT with degarelix.
Are You a Good Fit for This Trial?
Men over 18 with newly diagnosed metastatic prostate cancer, who haven't had certain previous treatments for it. They should have a specific blood cell count, no brain or severe heart conditions, and not be HIV-positive. Participants must agree to use birth control during the trial and have an ECOG performance status of 0-2.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive docetaxel for up to 6 cycles every 21 days, followed by degarelix starting from cycle 5
Follow-up
Participants are monitored for safety and effectiveness after treatment, including PSA response and adverse events
Extension
Degarelix continues to be administered every 28 days for 5 more doses after the initial treatment phase
What Are the Treatments Tested in This Trial?
Interventions
- Degarelix
- Docetaxel
Degarelix is already approved in European Union, United States, Canada, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medical University of South Carolina
Lead Sponsor
Ferring Pharmaceuticals
Industry Sponsor
Pierre-Yves Berclaz
Ferring Pharmaceuticals
Chief Medical Officer since 2023
MD from the University of Lausanne, PhD in Molecular Biology from the Cincinnati College of Medicine
Jean-Frédéric Paulsen
Ferring Pharmaceuticals
Chief Executive Officer since 2023
Master’s degree in Finance from the London School of Economics and Political Science